A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination
JNCI Monographs · 01.11.2024 · 2024 (67) · 417-423
DOI: 10.1093/jncimonographs/lgae040 ↗Kurz gefasst
Fachartikel in der Zeitschrift JNCI Monographs, online erschienen am 12.11.2024. Verfasst von Nicole G Campos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Hauptthemen laut MEDLINE: Papillomavirus Vaccines, Uterine Cervical Neoplasms, Papillomavirus Infections. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Cancer Institute Intramural Research Program, Cancer Cures Moonshot Initiative: Accelerated Control of Cervical Cancer, NIH.
Abstract (Originalsprache)
One-dose prophylactic HPV vaccination of pre-adolescents may reduce cervical cancer deaths dramatically in lower-resource settings, but the benefits of achieving immediate high coverage among pre-adolescents would not be realized for 20 to 40 years. Prophylactic vaccine efficacy is reduced after sexual debut, and current therapeutic intervention candidates designed to treat existing HPV infections or precancerous lesions have yielded insufficient evidence to warrant widespread use. However, we are developing a feasible, scalable, high-quality cervical screening approach that could prevent hundreds of thousands of deaths, while we work to achieve high coverage of one-dose vaccination for adolescent cohorts. A time-limited “one screen” campaign approach for lower-resource settings could complement parallel efforts to achieve high coverage with one-dose vaccination. This screen-triage-treat strategy would target the highest risk groups of screening age (ie, 25 to 49 years) for once-in-a-lifetime HPV testing of self-collected samples using a low-cost accurate HPV test; subsequent triage relying on extended genotyping and a validated deep-learning algorithm for automated visual evaluation (AVE) would stratify management based on risk to provide treatment for those most likely to develop cancer without overburdening health care systems. Early efficacy of this approach has been demonstrated in 9 countries within the HPV-AVE (PAVE) Study Consortium. We estimate that the cost per death averted of a screen-triage-treat campaign is of similar magnitude to prophylactic vaccination. We do not envision perpetual investment in ubiquitous brick-and-mortar screening programs if “one dose, one screen” is implemented with high coverage and targets the highest-risk populations. In collaboration with in-country stakeholders, efforts to ensure acceptability, risk communication, and cost-effectiveness are underway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Health Decision Science, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
- Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
- ISGlobal, Barcelona, Spain.
ORCID-Profile: Nicole G Campos
Förderung
- National Cancer Institute Intramural Research Program
- Cancer Cures Moonshot Initiative: Accelerated Control of Cervical Cancer
- NIH
Zitieren
APA
Campos, N. G., Lowy, D. R., de Sanjosé, S., & Schiffman, M. (2024). A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination. JNCI Monographs, 2024(67), 417-423. https://doi.org/10.1093/jncimonographs/lgae040
Vancouver
Campos NG, Lowy DR, de Sanjosé S, Schiffman M. A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination. JNCI Monographs. 2024;2024(67):417-423. doi:10.1093/jncimonographs/lgae040
BibTeX
@article{Campos2024,
author = {Campos, Nicole G and Lowy, Douglas R and de Sanjosé, Silvia and Schiffman, Mark},
title = {A cervical cancer control strategy for lower-resource settings: interventions to complement one-dose HPV vaccination},
journal = {JNCI Monographs},
year = {2024},
volume = {2024},
number = {67},
pages = {417--423},
doi = {10.1093/jncimonographs/lgae040}
}
EUVIMED